3Aoki Y, Tosato G. HIV-I Tat enhances Kaposi's sarcoma-associated herpesvirus (KSHV) inffectivity [ J]. Blood ,2004,104:810 - 814.
4Bower M, Weir J, Francis N, et al. The effect of HAART4 consecutive patients with AIDS-related Kaposi' s sarcoma [ J]. AIDS, 2009, 24( 13 ) : 1701 - 1706.
5Cattelan A, Calabrb M, De Rossi A, et al. Long-term clin- ical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy[ J]. Int J Oncol, 2005, 27(3) : 779-785.
6Lebb6 C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma [ J 1. AIDS, 1998,12 (7) : F45-F49.
7Flaitz CM. Role of intratesional vinblastine administration in treatment of intraoral kaposi, s sarcoma in AIDS [ J ]. Oral oncol Eur Cancer, 1995, 31 (4) :280-285.
8Ebrahim SH, Abdullah AS, Mckenna M, et al. AIDS-defining cancers in Western Europe, 1994-2001 [ J ]. AIDS Patient Care STDS, 2004, 18 (9) :501-508.
9Franceschi S, Dal Maso L, Rickenbach M, et al. Kaposi sarcoma inci- dence in the Swiss HIV Cohort Study before and after highly active an- tiretroviral therapy [ J ]. Br J Cancer,2008,99 (5) :800-804.
10Bohlius J, Valeri F, Maskew M, et al. Kaposis sarcoma in HIV-infected patients in South Africa: multicohort study in the antiretroviral therapy era[ J ]. Int J Cancer,2014,135 ( 11 ) :2644-2652.
